Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677926 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1CHRNA7HTR3AMEN1 | |
| SCHEMBL32677941 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1CHRNA7HTR3AMEN1 | |
| SCHEMBL32677942 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1CHRNA7HTR3AMEN1 | |
| SCHEMBL32677939 | 0.83 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1CHRNA7HTR3AMEN1 | |
| SCHEMBL32677937 | 0.83 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1CHRNA7HTR3AMEN1 | |
| SCHEMBL16504401 | 0.79 | TSHR (0.41) | MEN1KMT2AKDM4E | |
| SCHEMBL32677916 | 0.75 | FAAH (0.35) | SMN1; SMN2ALDH1A1CHRNA7HTR3AKMT2A | |
| SCHEMBL32677913 | 0.75 | FAAH (0.35) | SMN1; SMN2ALDH1A1CHRNA7HTR3AKMT2A | |
| SCHEMBL19630869 | 0.75 | PDE4B (0.39) | ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL16505100 | 0.70 | KMT2A (0.37) | ALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055109-A1 | IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2026-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055109-A1 | IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS | HTR7, HTR3B, HTR3A | SMN1; SMN2 982/4885ALDH1A1 1379/4885CHRNA7 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.